Poisonous pill

14 February 2018 By Alec Macfarlane

The struggling U.S. vitamin vendor is selling a 40 pct stake to Harbin Pharmaceutical. That should help open the door to a big market. The price is steep, though. Convertible shares come with nearly half the board, giving GNC’s partner the muscle to block any future rescue deals.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)